Crizotinib medical insurance reimbursement conditions

The original drug Crizotinib (Crizotinib) has been marketed in China and is included in the scope of medical insurance, but only patients who meet the indications can be reimbursed by medical insurance, including patients with anaplastic lymphoma kinase (ALK) positive locally advanced or metastatic non- Patients with small cell lung cancer or ROS1-positive advanced non-small cell lung cancer (NSCLC) patients who do not meet the conditions can only purchase them at their own expense. The current price of imported drugs is still relatively high.

ALK and ROS1 belong to a family of proteins called receptor tyrosine kinases (RTKs) that are involved in cell growth. In "ALK-positive" or "ROS1-positive" tumors, the ALK or ROS1 protein is abnormally active, which can promote uncontrolled growth of cells and the development of new blood vessels that supply the cells. The active substance in crizotinib is an RTK inhibitor. It works primarily by blocking the activity of ALK or ROS1, including when genetic changes are present, thereby reducing the growth and spread of cancer in ALK-positive ALCL and IMT and ALK- and ROS1-positive non-small cell lung cancer.

The domestically marketed original crizotinib may cost around RMB 15,000 per box; the Turkish original version of crizotinib sold overseas may cost more than RMB 10,000 per box (the price may fluctuate due to exchange rates), which is expensive. There are also cheaper generic crizotinib drugs available overseas. The ingredients are basically similar to those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Bangladesh pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to exchange rates).